2-benzyl-4-bromobenzoic acid | 857005-14-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzyl-4-bromobenzoic acid
• 英文别名: 2-Benzyl-4-brom-benzoesaeure
• CAS: 857005-14-2
• 化学式: C₁₄H₁₁BrO₂
• 分子量: 291.144
• InChiKey: OUGBMNAFMFKNSR-UHFFFAOYSA-N

物化性质

• 熔点：
  143.5 °C
• 沸点：
  407.2±33.0 °C(Predicted)
• 密度：
  1.473±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-benzyl-4-bromobenzoic acid 在 硼烷四氢呋喃络合物 作用下， 生成 2-benzyl-4-bromobenzyl alcohol
  参考文献：
  名称：

  Potential Modes of Interaction of 9-Aminomethyl-9,10-dihydroanthracene (AMDA) Derivatives with the 5-HT_2A Receptor: A Ligand Structure-Affinity Relationship, Receptor Mutagenesis and Receptor Modeling Investigation

  摘要：

  The effects of 3-position substitution of 9-aminomethyl-9,10-dihydroanthracene (AMDA) on 5-HT2A receptor affinity were determined and compared to a parallel series of DOB-like 1-(2,5-dimethoxyphenyl)-2-aminopropanes substituted at the 4-position. The results were interpreted within the context of 5-HT2A receptor models that suggest that members of the DOB-like series call bind to the receptor in two distinct modes that correlate with the compounds' functional activity. Automated ligand docking and molecular dynamics suggest that all of the AMDA derivatives, the parent of which is a 5-HT2A antagonist, bind in a fashion analogous to that for the sterically demanding antagonist DOB-like compounds. The failure of the F340(6.52)L mutation to adversely affect the affinity of AMDA and the 3-bromo derivative is consistent with the proposed modes of orientation. Evaluation of ligand-receptor complex models suggest that a valine/threonine exchange between the 5-HT2A and D-2 receptors may be the origin of selectivity for AMDA and two substituted derivatives.

  DOI：

  10.1021/jm800771x
• 作为产物：
  描述：

  5-溴苯酞 在 磷化氢 、 sodium hydroxide 、 水 、 溴 、 碘 、 magnesium 、 溶剂黄146 作用下， 以 四氢呋喃 、 溴苯 、 水 为溶剂， 反应 11.25h， 生成 2-benzyl-4-bromobenzoic acid
  参考文献：
  名称：

  WO2008/151211

  摘要：

  公开号：

文献信息

• DEPROTECTION METHOD FOR TETRAZOLE COMPOUND
  申请人：API CORPORATION

  公开号：US20150239854A1

  公开（公告）日：2015-08-27

  The present invention relates to a method of deprotecting a tetrazole compound, useful as an intermediate for angiotensin II receptor blockers, and provides a novel production method of angiotensin II receptor blockers. Provided is a production method of a compound represented by the formula [3] or [4] or a salt thereof, including (i) reducing a compound represented by the formula [1] or [2] or a salt thereof in the presence of a metal catalyst and an alkaline earth metal salt, or (ii) reacting the compound with a particular amount of Brønsted acid: wherein each symbol is as defined in the present specification.

  本发明涉及一种去保护四唑化合物的方法，该方法作为血管紧张素II受体拮抗剂的中间体，并提供了一种新颖的血管紧张素II受体拮抗剂的生产方法。 提供了一种由式[3]或[4]表示的化合物或其盐的生产方法，包括(i)在金属催化剂和碱土金属盐的存在下还原式[1]或[2]表示的化合物或其盐，或(ii)将该化合物与特定量的Brønsted酸反应： 其中每个符号如本说明书中所定义。
• Benzoic acid derivatives and related compounds as antiarrhythmic agents
  申请人：——

  公开号：US20020137968A1

  公开（公告）日：2002-09-26

  Benzoic acid derivatives of the formula I 1 where X is oxygen, sulfur, —NH, —NR 1 , —N—CN, —N—OR 1 or —N—NO 2 ; Y is a single bond, —C═C—, or —NH; R 1 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclo, or (heterocyclo)alkyl; and R 2 is aryl or heterocyclo. The compounds of formula I are useful in the treatment of arrhythmia.

  公式I的苯甲酸衍生物 其中X为氧、硫、—NH、—NR 1 、—N—CN、—N—OR 1 或—N—NO 2 ； Y为单键、—C═C—或—NH； R 1 为烷基、烯基、炔基、芳基、环烷基、杂环烷基或(杂环烷基)；和 R 2 为芳基或杂环烷基。公式I的化合物在心律失常的治疗中很有用。
• [EN] BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS ANTIARRHYTHMIC AGENTS<br/>[FR] DERIVES D'ACIDE BENZOÏQUE ET COMPOSES APPARENTES UTILISES COMME AGENTS ANTIARYTHMIQUES
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：WO1998037068A1

  公开（公告）日：1998-08-27

  (EN) Benzoic acid derivatives of formula (I) where X is oxygen, sulfur, -NH, -NR1, -N-CN, -N-OR1 or -N-NO2; Y is a single bond, -C=C-, or -NH; R1 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclo, or (heterocyclo)alkyl; and R2 is aryl or heterocyclo. The compounds of formula (I) are useful in the treatment of arrhythmia.(FR) L'invention concerne des dérivés d'acide benzoïque de la formule (I), dans laquelle: X représente oxygène, soufre, -NH, -NR1, -N-CN, -N-OR1 ou bien -N-NO2; Y représente une liaison simple, -C=C-, ou bien -NH; R1 représente alkyle, alcényle, alkynyle, aryle, cycloalkyle, hétérocyclo ou (hétérocyclo)alkyle; et R2 représente aryle ou hétérocyclo. Les composés de formule (I) sont utiles dans le traitement de l'arythmie.

  （中文翻译）公式（I）中的苯甲酸衍生物，其中X代表氧、硫、-NH、-NR1、-N-CN、-N-OR1或-N-NO2；Y代表单键、-C=C-或-NH；R1代表烷基、烯基、炔基、芳基、环烷基、杂环烷基或（杂环烷基）烷基；R2代表芳基或杂环烷基。公式（I）中的化合物在心律失常的治疗中有用。
• SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS
  申请人：CAULFIELD Thomas J.

  公开号：US20100113462A1

  公开（公告）日：2010-05-06

  The present invention relates to novel compounds of the formula I: wherein in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

  本发明涉及公式I的新化合物：其中在其任何立体异构形式或立体异构形式的混合物中以任何比例，或其生理上可接受的盐，其中取代基如此描述。这些创新化合物具有CXCR5抑制活性，特别适用于治疗或预防各种炎症性疾病，例如类风湿性关节炎，多发性硬化症，红斑狼疮，克罗恩病，与人类CXCR5受体调节相关。
• Substituted benzoylamino-indan-2-carboxylic acids and related compounds
  申请人：Caulfield Thomas Joseph

  公开号：US08569535B2

  公开（公告）日：2013-10-29

  The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

  本发明涉及公式Ia的新化合物：以其立体异构体形式或任何比例的立体异构体混合物或其生理上可接受的盐，其中取代基如本文所述。这些创新化合物具有CXCR5抑制活性，并且在治疗或预防各种炎症性疾病方面特别有用，例如类风湿性关节炎，多发性硬化症，狼疮，克隆氏病，与人类CXCR5受体调节有关。